Teresa Macarulla

Research interests

Publications

• The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

  ESMO Open · 2023 · https://doi.org/10.1016/j.esmoop.2023.101567

• Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00242-5

• NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)01366-1

• Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.21.01604

• Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

  ˜The œLancet. Gastroenterology & hepatology · 2021 · https://doi.org/10.1016/s2468-1253(21)00196-5

• Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

  JAMA Oncology · 2021 · https://doi.org/10.1001/jamaoncol.2021.3836

• BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0880-x

• Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00590

• Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30157-1

• Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903387

• First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

  Cancer Discovery · 2019 · https://doi.org/10.1158/2159-8290.cd-19-0555

• Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

  British Journal of Cancer · 2018 · https://doi.org/10.1038/s41416-018-0246-z

• mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  Nature · 2017 · https://doi.org/10.1038/nature22964

• Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.75.5009

• Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)00986-1

• Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transition

  International Journal of Cancer · 2013 · https://doi.org/10.1002/ijc.28387

• Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.42.8201

• Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

  Journal of Clinical Investigation · 2010 · https://doi.org/10.1172/jci37539

• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

  The Lancet Oncology · 2010 · https://doi.org/10.1016/s1470-2045(10)70130-3

• Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.14.5482

Current projects

No projects listed.